Varivax

Varivax is a live, attenuated varicella vaccine designed to protect against chickenpox (varicella zoster virus). This Merck-produced vaccine is administered via injection to stimulate immunity. It is a preventive measure for individuals at risk of varicella infection. Store in a refrigerated environment to maintain potency.

Varivax is used to prevent chickenpox (varicella) in individuals who have not had the disease or been previously vaccinated. It is recommended for children, adolescents, and adults without evidence of immunity. The vaccine works by introducing a weakened form of the varicella virus to trigger an immune response, reducing the risk of infection. It is also used for post-exposure prophylaxis in certain cases.

After vaccination, some individuals may experience mild effects such as redness, swelling, or pain at the injection site. Low-grade fever, mild rash, or general discomfort can occur within a few days. These effects are typically temporary and indicate the body’s immune response. Serious reactions are rare but should be reported to a healthcare provider.

Varivax should be handled with care to maintain its potency; store refrigerated between 2°C and 8°C (36°F and 46°F) and protect from light. Avoid freezing. Individuals with weakened immune systems, active untreated tuberculosis, or severe allergic reactions to vaccine components should consult a healthcare provider before use. Pregnant women should delay vaccination until after childbirth.

Varivax may interact with immunosuppressive therapies, including corticosteroids or chemotherapy, potentially reducing its effectiveness. Avoid receiving the vaccine within 1 month of blood transfusions or antibody-containing products unless directed by a healthcare provider. Live vaccines should not be administered simultaneously with certain other live vaccines without medical guidance.